Form 4: BioLife Solutions CTO Sells Shares to Cover Tax Obligations
Insider Transaction Report
BioLife Solutions Chief Technology Officer Sean Werner sold 1,115 shares of common stock for $21.22 per share to satisfy tax withholding obligations under a pre-arranged trading plan.
Summary
- Sean Werner, Chief Technology Officer of BioLife Solutions Inc. (BLFS), reported the sale of 1,115 shares of common stock.
- The transaction occurred on July 18, 2025, with the filing submitted on July 22, 2025.
- The shares were sold at a price of $21.22 per share, totaling approximately $23,660.30.
- The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted by Mr. Werner effective July 17, 2024.
- The primary purpose of this sale was to cover tax withholding obligations associated with the vesting of restricted stock shares.
- Following this transaction, Sean Werner beneficially owns 26,495 shares of BioLife Solutions common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. This is a routine insider sale for tax purposes, pre-arranged under a 10b5-1 plan, which is generally not indicative of management's view on the company's future prospects or a significant event for the company's stock performance.
Positives
- The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled and transparent sale not based on new material non-public information.
Negatives
- An insider sale, even for tax purposes, reduces the direct ownership stake of a key executive in the company.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This Form 4 filing reports a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive dynamics within the biopreservation or cell and gene therapy tools sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The sale was conducted under a Rule 10b5-1(c) trading plan, adopted effective July 17, 2024. This plan allows insiders to pre-arrange trades to avoid accusations of trading on material non-public information. | 07/17/2024 | Enhances transparency and provides an affirmative defense against insider trading allegations for the reported transaction. |
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in direct insider ownership, but its pre-planned, tax-related nature suggests no negative implications for company fundamentals or future performance.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Effective date of the Rule 10b5-1(c) trading plan adopted by Sean Werner. |
| 07/18/2025 | Date of the reported sale transaction of common stock by Sean Werner. |
| 07/22/2025 | Date the Form 4 filing was signed and submitted to the SEC. |
Keywords
BioLife Solutions, BLFS, Sean Werner, Chief Technology Officer, Insider Sale, Form 4, SEC Filing, Stock Transaction, Rule 10b5-1, Tax Withholding, Restricted Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.